(Q44712179)

5 December 2017

title

The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants (English)

1 reference

5 December 2017

Gaetano Ciancio

1

1 reference

5 December 2017

Adela Mattiazzi

2

1 reference

5 December 2017

David Roth

3

1 reference

5 December 2017

Warren Kupin

4

1 reference

5 December 2017

Joshua Miller

5

1 reference

5 December 2017

George W Burke

6

1 reference

5 December 2017

publication date

1 October 2003

1 reference

5 December 2017

published in

Clinical Transplantation

1 reference

5 December 2017

volume

17

1 reference

5 December 2017

issue

5

1 reference

5 December 2017

page(s)

428-432

1 reference

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

The use of intravenous tacrolimus and mycophenolate mofetil as induction and maintenance immunosuppression in simultaneous pancreas--kidney recipients with previous transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Use of tacrolimus and mycophenolate mofetil as induction and maintenance in simultaneous pancreas-kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Long-term renal retransplantation and graft survival rates at our center

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Analysis of Infectious Complications Occurring After Solid-Organ Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

7 January 2021

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

7 January 2021

Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

7 January 2021

A randomized prospective comparison of MALG with OKT3 for rescue therapy of acute myocardial rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

7 January 2021

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

7 January 2021

Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

7 January 2021

Successful retreatment of allograft rejection with OKT3

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

7 January 2021

Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00066.X

7 January 2021

10.1034/J.1399-0012.2003.00066.X

Identifiers

DOI

1 reference

5 December 2017

1 reference